nextcure.com (NXTC): Price-to-Projected Revenue Ratio

NXTC (NextCure Inc) - company brandmark

Will the reputable management of NextCure, Inc. (NXTC) ensure business success? Revenue growth is projected through the market launch of NC318 antibodies, which is supported by the forward price-to-sales ratio, currently standing at . However, fierce competition for capital and the risk of more efficient gene-editing methods emerging present serious challenges for the company.

NXTC NextCure Inc: Market Cap to Future Revenue Ratio in the range 07/04/2022 - 11/13/2026

Analytical breakdowns for NextCure Corporation (NXTC)

- stock price and consensus target price:
Stock Quotes NextCure|NXTC - Analyst Consensus Forecast
- stock exchange capitalization data:
Market Value NextCure Corporation|NXTC - Business Value
- book value of equity indicators:
Net Assets per Single Share NextCure|NXTC - Total Stockholders' Equity|Market Cap to Net Assets Ratio nextcure.com|NXTC - Company Balance Sheet Assets
- company total debt and liquidity indicators:
Total Debt to Equity Ratio NextCure, Inc.|NXTC - Long-Term Loans to Capital Ratio|Short-Term Debt to Capital NextCure, Inc.|NXTC - Aggregate Debt Obligations|Debts to Book Capitalization NextCure Corporation|NXTC - Long-Term Debt|Company Short-Term Debt NextCure|Quick Ratio nextcure.com
- business earnings and investment ratios data:
NXTC - Net Profit|Expected Profit NextCure, Inc.|NXTC - Market Cap to Net Income|Projected Price to Earnings NextCure Corp|NXTC - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization NextCure Corporation|NXTC - Operating profit before amortization|Net earnings per share (EPS TTM) NextCure|NXTC - Net earnings per one share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months nextcure.com|NXTC - Earnings per share growth this year|Expected earnings per share growth for next year NextCure, Inc.
- revenue and sales details:
NXTC - Company Total Sales|Projected Sales Volume NextCure|NXTC - Market Cap to Revenue|Forward Price-to-Revenue Multiple NextCure Corporation
Summary company analysis:NextCure NXTC
Manufactured products of NextCure Corporation

To find a balance between valuation and business quality, use the ratio of market capitalization to projected revenue, which measures the premium paid for future success. Since NextCure, Inc. (NXTC) has no commercial products pending FDA approval, the forward P/S trend allows for an assessment of how current market expectations align with drug development potential and the effectiveness of the company's cost management.

Competitor analysis

ImmunityBio - Forward Price-to-Revenue Multiple|Forward P/S Multiple Immunocore Holdings IMCR|JANX - Price-to-Projected Revenue Ratio|RCUS (Arcus Corp) - Market Cap to Projected Revenue|Zymeworks Inc. (ZYME) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio tangotx.com (TNGX)|Forward Price-to-Revenue Multiple IOVA|IMTX - Projected Price to Revenue|Forward Price-to-Revenue Multiple XNCR (Xencor Corp)|Price to Expected Revenue Ratio CMPX|Forward P/S Multiple REPL (Replimune Group, Inc.)|Forward Price to Sales LYEL|Innate Pharma - Forward P/S Multiple|Market Cap to Future Revenue Ratio Pyxis Oncology, Inc.|cgen.com (CGEN) - Price-to-Projected Revenue Ratio|IO Biotech Inc. - Forward Price to Sales|STRO (Sutro Biopharma, Inc.) - Forward P/S Multiple|Forward P/S Multiple minktherapeutics.com|Price-to-Projected Revenue Ratio Werewolf Therapeutics (HOWL)|IMMX: Future Price to Revenue|ALX Oncology Holdings - Forward Price-to-Revenue Multiple|cuebiopharma.com (CUE) - Market Cap to Future Revenue Ratio|PDSB - Price-to-Projected Revenue Ratio|SONN (Sonnet BioTherapeutics) - Market Cap to Projected Revenue|MAIA: Forward P/S Multiple|Market Cap to Future Revenue Ratio Liminatus Pharma Inc. (LIMN)|Forward Price-to-Revenue Multiple LVTX|Market Cap to Projected Revenue LPTX (Leap Tx)|Forward Price-to-Revenue Multiple INTS (Intensity Therapeutics)|Price to Expected Revenue Ratio SNSE|Forward P/S Multiple TOVX (Theriva Biologics)|GRTS - Forward Price-to-Revenue Multiple|KA: Forward Price-to-Revenue Multiple|NEXI - Forward P/S Multiple|turnstonebio.com (TSBX) - Price-to-Projected Revenue Ratio|vaccinex.com - Forward Price to Sales|HARP (Harpoon Therapeutics, Inc.) - Forward P/S Multiple